126 related articles for article (PubMed ID: 29198127)
21. Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells.
Jovanović MP; Jaković L; Bogdanović A; Marković O; Martinović VC; Mihaljević B
Vojnosanit Pregl; 2009 Sep; 66(9):738-43. PubMed ID: 19877554
[TBL] [Abstract][Full Text] [Related]
22. The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma.
Pătraşcu AM; Rotaru I; Olar L; Pătraşcu Ş; Ghiluşi MC; NeamŢu SD; Nacea JG; Gluhovschi A
Rom J Morphol Embryol; 2017; 58(3):837-843. PubMed ID: 29250662
[TBL] [Abstract][Full Text] [Related]
23. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma.
Møller MB; Ino Y; Gerdes AM; Skjødt K; Louis DN; Pedersen NT
Leukemia; 1999 Mar; 13(3):453-9. PubMed ID: 10086736
[TBL] [Abstract][Full Text] [Related]
24. Aberrant expression of p53, p16INK4a and Ki-67 as basic biomarker for malignant progression of oral leukoplakias.
Nasser W; Flechtenmacher C; Holzinger D; Hofele C; Bosch FX
J Oral Pathol Med; 2011 Sep; 40(8):629-35. PubMed ID: 21435003
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ
Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692
[TBL] [Abstract][Full Text] [Related]
26. p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status.
Richardson AI; Zhang D; Woodroof J; Cui W
Hum Pathol; 2019 Apr; 86():21-31. PubMed ID: 30496802
[TBL] [Abstract][Full Text] [Related]
27. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays.
Terzi A; Saglam EA; Barak A; Soylemezoglu F
Pathol Res Pract; 2008; 204(5):305-14. PubMed ID: 18374497
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic analysis of 51 cases of primary nodal diffuse large B-cell lymphomas].
Li D; Li GD; Liu WP; Zhang WY; Li FY; Liao DY
Zhonghua Xue Ye Xue Za Zhi; 2005 Apr; 26(4):223-6. PubMed ID: 15949265
[TBL] [Abstract][Full Text] [Related]
29. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma.
Straume O; Sviland L; Akslen LA
Clin Cancer Res; 2000 May; 6(5):1845-53. PubMed ID: 10815907
[TBL] [Abstract][Full Text] [Related]
30. [Expression and clinical significance of Ki-67 in diffuse large B cell lymphoma].
Zhou Y; Zhao Y; Bo J; Li YF; Ma C; Shi YN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1162-6. PubMed ID: 24156426
[TBL] [Abstract][Full Text] [Related]
31. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma].
Wen JJ; Liu ZB; Xu J; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791
[TBL] [Abstract][Full Text] [Related]
32. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
33. Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity.
Angiero F; Berenzi A; Benetti A; Rossi E; Del Sordo R; Sidoni A; Stefani M; Dessy E
Anticancer Res; 2008; 28(5A):2535-9. PubMed ID: 19035275
[TBL] [Abstract][Full Text] [Related]
34. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
[No Abstract] [Full Text] [Related]
35. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.
Han Y; Yang J; Liu P; He X; Zhang C; Zhou S; Zhou L; Qin Y; Song Y; Sun Y; Shi Y
Oncologist; 2019 Nov; 24(11):e1251-e1261. PubMed ID: 30952824
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.
Kaune KM; Neumann C; Hallermann C; Haller F; Schön MP; Middel P
Exp Dermatol; 2011 Apr; 20(4):331-5. PubMed ID: 21410763
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study.
Bian C; Li Z; Xu Y; Wang J; Xu L; Shen H
World J Surg Oncol; 2015 Mar; 13():128. PubMed ID: 25890228
[TBL] [Abstract][Full Text] [Related]
38. Mad2 overexpression is associated with high cell proliferation and reduced disease-free survival in primary gastrointestinal diffuse large B-cell lymphoma.
Chen F; Liu S; Zhou Y; Shen H; Zuo X
Hematology; 2016 Aug; 21(7):399-403. PubMed ID: 27077767
[TBL] [Abstract][Full Text] [Related]
39. Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors.
Sugianto J; Sarode V; Peng Y
Hum Pathol; 2014 Apr; 45(4):802-9. PubMed ID: 24560018
[TBL] [Abstract][Full Text] [Related]
40. Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group.
Shiozawa E; Takimoto M; Makino R; Adachi D; Saito B; Yamochi-Onizuka T; Yamochi T; Shimozuma J; Maeda T; Kohno Y; Kawakami K; Nakamaki T; Tomoyasu S; Shiokawa A; Ota H
Leuk Res; 2006 Jul; 30(7):859-67. PubMed ID: 16406514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
